 |
|
A Pilot Study of Buspirone in Attention-Deficit Hyperactivity Disorder
Louis H. McCormick, MD;
Gaspard T. Rizzuto, PhD;
Hope B. Knuckles
Arch Fam Med. 1994;3(1):68-70.
References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: The American Psychiatric Association; 1987:50-53.
2. Coleman WL, Levine MD. Attention deficits in adolescents: description, evaluation and management. Pediatr Rev. 1988;9:287-298.
FREE FULL TEXT
3. Barkley RA, Murphy JV. Treating attention-deficit hyperactivity disorder: medication and behavior management training. Pediatr Ann. 1991;20:256-266.
PUBMED
4. Klorman R, Brumaghim JT, Fitzpatrick PA, Borgstedt AD. Clinical effects of a controlled trial of methylphenidate on adolescents with attention deficit disorder. J Am Acad Child Adolesc Psychiatry. 1990;29:702-709.
PUBMED
5. Brown RT, Sexson SB. A controlled trial of methylphenidate in black adolescents. Clin Pediatr (Phila). 1988;27:74-81.
FREE FULL TEXT
6. Gastfriend DR, Biederman J, Jellinek MS. Desipramine in the treatment of adolescents with attention deficit disorder. Am J Psychiatry. 1984;141:906-908.
PUBMED
7. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD, I: efficacy. J Am Acad Child Adolesc Psychiatry. 1989;28:777-784.
PUBMED
8. Cantwell DP. Pharmacotherapy of ADD in adolescence: what do we know, where should we go, how should we do it? Psychopharmacol Bull. 1985;21:251-257.
PUBMED
9. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebocrossover therapeutic trial. J Am Acad Child Adolesc Psychiatry. 1985;24:617-629.
10. Buspirone: a non-benzodiazepine for anxiety. Med Lett Drugs Ther. 1986;28:117-118.
PUBMED
11. Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ. Review of the sideeffect profile of buspirone. Am J Med. 1986;80(suppl_3B):17S-21S.
12. Kranzler HR. Use of buspirone in an adolescent with overanxious disorder. J Am Acad Child Adolesc Psychiatry. 1988;27:789-790.
PUBMED
13. Rakel RE. Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. South Med J. 1990;83:194-198.
PUBMED
14. Ratey JJ, Sovner R, Mikkelsen E, Chmielinski HE. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J Clin Psychiatry. 1989;50:382-384.
PUBMED
15. Realmuto GM, August GJ, Garfinkel BD. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol. 1989;9:122-125.
PUBMED
16. Quiason N, Ward D, Kitchen T. Buspirone for aggression. J Am Acad Child Adolesc Psychiatry. 1991;30:1026.
PUBMED
17. Balon R. Buspirone for attention deficit hyperactivity disorder? J Clin Psychopharmacol. 1990;10:77.
PUBMED
18. Conners CK. Rating scales for use in drug studies with children. Psychopharmacol Bull. 1973;9:24-84.
19. Werry JS. Measures in pediatric psychopharmacology. In: Werry JS, ed. Pediatric Psychopharmacology: The Use of Behavior Modifying Drugs in Children. New York, NY: Brunner Mazel; 1978:29-78. 20. Goyettte CH, Conners CK, Ulrich RF. Normative data on revised Conners' Parent and Teacher Rating scales. J Abnorm Child Psychol. 1978;6:221-236.
PUBMED
21. Wilson JM, Kiessling LS. What is measured by the Conners' Teacher Behavior Rating Scale: replication of factor analysis. J Dev Behav Pediatr. 1988;9:271-278.
PUBMED
22. Wallenstein S, Fisher AC. The analysis of the two-period repeated measurements crossover design with application to clinical trials. Biometrics. 1977;33:261-269.
PUBMED
23. Rostain AL. Attention deficit disorders in children and adolescents. Pediatr Clin North Am. 1991;38:607-633.
PUBMED
24. Feighner JP, Cohn JB. Analysis of individual symptoms in generalized anxiety: a pooled, multistudy, double-blind evaluation of buspirone. Neuropsychobiology. 1989;21:124-130.
PUBMED
25. Silver LB. Controversial approaches to treating learning disabilities and attention deficit disorder. AJDC. 1986;140:1045-1052.
PUBMED
26. Pelham WE, Greenslade KE, Vodde-Hamilton M, et al. Relative efficay of long-acting stimulants on children with attention deficit—hyperactivity disorder: a comparison of standard methylphenidate, sustained release methylphenidate, sustained release dextroamphetamine, and pemoline. Pediatrics. 1990;86:226-237.
FREE FULL TEXT
27. Kelly DP, Aylward GP. Attention deficits in school aged children and adolescents. Pediatr Clin North Am. 1992;39:487-513.
PUBMED
28. Eison AS, Temple DL. Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am J Med. 1986;80(suppl 3B):1S-9S.
29. Taylor DP, Becker JA, Crane M, Hyslop DK, Riblet LA, Temple DL. Chronic treatment with buspirone reduces type two serotonin binding sites. Soc Neurosci Abstr. 1983;9:435.
30. VanderMaelen CP, Wilderman RC. Iontophoretic and systemic administration of the non-benzodiazepine anxiolytic drug buspirone causes inhibition of serotonergic dorsal raphe neurons in rats. Federation Proc. 1984;43:947.
|
